EP
TEVA icon

Edgestream Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Edgestream Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-242,565
Closed -$2.36M – 578
2021
Q3 		$2.36M Buy
+242,565
New +$2.27M 0.15% 214
2021
Q1 		– Sell
-666,361
Closed -$6.43M – 445
2020
Q4 		$6.43M Buy
+666,361
New +$6.38M 0.32% 111

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Edgestream Partners's TEVA Position: Q4 2021 in Review

Edgestream Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 242,565 shares — an estimated $2.36M sold.

Edgestream Partners first reported a position in TEVA in Q4 2020 and held it in 2 quarters. The position peaked at $6.43M in Q4 2020. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Edgestream Partners reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Edgestream Partners sold 242,565 Teva Pharmaceuticals shares in Q4 2021, an estimated $2.36M.
  • Edgestream Partners first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Edgestream Partners's Teva Pharmaceuticals position peaked at $6.43M in Q4 2020.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Edgestream Partners's 13F filing for Q4 2021, filed 15 Feb 2022.